Journal
AGEING RESEARCH REVIEWS
Volume 11, Issue 4, Pages 450-459Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.arr.2012.03.005
Keywords
A beta PP; A beta; FMRP; hnRNP C; Nucleolin; Post-transcriptional gene regulation
Categories
Funding
- National Institutes of Health [R01-AG10675, RO1-DA026067, P30-HD03352, T32-AG00213]
- Alzheimer's Drug Discovery Foundation
- FRAXA Research Foundation
- Wisconsin Comprehensive Memory Program
Ask authors/readers for more resources
Amyloid beta-protein precursor (A beta PP) is cleaved by beta- and gamma-secretases to liberate amyloid beta (A beta), the predominant protein found in the senile plaques associated with Alzheimer's disease (AD) and Down syndrome (Masters et al., 1985). Intense investigation by the scientific community has centered on understanding the molecular pathways that underlie the production and accumulation of A beta Therapeutics that reduce the levels of this tenacious, plaque-promoting peptide may reduce the ongoing neural dysfunction and neuronal degeneration that occurs so profoundly in AD. A beta PP and A beta production are highly complex and involve still to be elucidated combinations of transcriptional, post-transcriptional, translational and post-translational events that mediate the production, processing and clearance of these proteins. Research in our laboratory for the past two decades has focused on the role of RNA binding proteins (RBPs) in mediating the post-transcriptional as well as translational regulation of APP messenger RNA (mRNA). This review article summarizes our findings, as well as those from other laboratories, describing the identification of regulatory RBPs, where and under what conditions they interact with APP mRNA and how those interactions control A beta PP and A beta synthesis. (C) 2012 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available